1
2
3
4
Image Name

About Wanbangde

About WEPON

Image Name

Wanbande Group

Image Name

Pharmaceutical Holdings

Image Name

API Division

Image Name

Company Profile

Company profile

Detail

Founded in 1970, Wanbangde Pharmaceutical Group is headquartered in Wenling City, Taizhou, Zhejiang Province. It is a high-tech enterprise dedicated to the research, development, manufacturing, and sales of modern traditional Chinese medicines, as well as active pharmaceutical ingredients and finished dosage forms. The company currently has six subsidiaries and holds 186 drug production approvals, covering 14 different dosage forms.

Image Name

Brand Advantages

Top 100 Chinese National Medicine Brand Enterprises

China's Most Dynamic Pharmaceutical Industry Enterprise

Top 100 Traditional Chinese Medicine Enterprises

Image Name

R&D Advantages

Model Academician and Expert Workstation

Provincial Enterprise Research Institute

Provincial Enterprise Technology Center

Image Name

Product Advantages

"Establishing a product portfolio characterized by natural herbal medicines, primarily focused on cardiovascular and central nervous system drugs, while complementing it with medications for the respiratory system and other therapeutic areas—leveraging the dual advantage of 'raw materials + formulations' for a comprehensive, multi-pronged approach."

Image Name

Economies of scale

Modern factory facilities are fully equipped;

Having a stable supplier network;

1
2
3
4
5
Image Name

News and Information

News

Detail

Good News | Warm Congratulations to Wanbande Pharmaceutical Group Co., Ltd. (Registered Trademark: wepon), which has been honored with the third batch of the "Taizhou Time-Honored Brand" title!

Good News | Warm Congratulations to Wanbande Pharmaceutical Group Co., Ltd. (Registered Trademark: wepon), which has been honored with the third batch of the "Taizhou Time-Honored Brand" title!

2025

04-14

New peptide candidate compound: Preclinical studies in the metabolic field show promising progress.

In the face of today’s alarming global obesity epidemic, Wanbangde Pharmaceutical Group Co., Ltd. has strategically developed a novel class of small-molecule cyclic peptides targeting melanocortin receptors (MCR), aiming to deliver a differentiated therapeutic approach in the metabolic disease space. Recently, the company’s groundbreaking new candidate compound has yielded promising preclinical data, demonstrating the anticipated effects of "reducing fat while preserving muscle" in obese mouse models.

2025

04-14

[“Station” Success Report] | Wanbangde Pharmaceutical Group’s Postdoctoral Research Workstation Gains New Talent, Accelerating the Advancement of Innovative Drug Development!

On February 28, 2025, the Wanbande Pharmaceutical Group Postdoctoral Research Station achieved a significant milestone in the field of innovative drug development, as Dr. Hong Chunlan and Dr. Mao Yuling officially joined the station and successfully defended their project proposals. This marks another powerful boost of scientific momentum for Wanbande Pharmaceutical Group in its pursuit of groundbreaking pharmaceutical innovations, underscoring the company’s robust expertise and unwavering commitment to cutting-edge medical research.

2025

04-14

Mingjie Pharma's inaugural national CMC pharmacy salon tour for 2025 concludes successfully | Wanbangde Pharmaceutical deeply engages in technical exchanges

On March 1, 2025, the first stop of Mingjie Pharmaceutical's "2025 National Tour Salon on Comprehensive CMC Research Strategies for Pharmaceuticals" was successfully held at Wanbangde Pharmaceutical Group Co., Ltd. With the theme "Empowering the Entire Lifecycle of Drug Development and Building a New Ecosystem for Quality Research," the event drew full participation from Wanbangde's entire R&D team. Together, both sides engaged in an in-depth dialogue centered on critical quality research issues throughout the drug development and manufacturing process, jointly exploring emerging trends in industry technology.